Evy LundgrenÅkerlund

Evy LundgrenÅkerlund

Company: Xintela

Job title: Chief Executive Officer

Seminars:

Targeting integrin α10β1 in Aggressive Cancer 11:00 am

Targinta has selected its first lead drug candidate, TARG10, a therapeutic antibody targeting integrin α10β1 TARG10 has shown strong activity on cancer cells and in preclinical tumor models, with significant inhibitory effects on both growth and metastasis in triplenegative breast cancer modelsRead more

day: Day Two

Integrin α10β1 Selected MSCs – A Superior Therapeutic Approach 10:30 am

Xintela’s integrin biomarker technology platform has potential to reach $10bn commercials through OA, GBM and TNBCRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.